Jin Seok Ahn

22.4k total citations · 4 hit papers
452 papers, 13.5k citations indexed

About

Jin Seok Ahn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jin Seok Ahn has authored 452 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 318 papers in Oncology, 237 papers in Pulmonary and Respiratory Medicine and 130 papers in Cancer Research. Recurrent topics in Jin Seok Ahn's work include Lung Cancer Treatments and Mutations (181 papers), Lung Cancer Research Studies (103 papers) and Breast Cancer Treatment Studies (70 papers). Jin Seok Ahn is often cited by papers focused on Lung Cancer Treatments and Mutations (181 papers), Lung Cancer Research Studies (103 papers) and Breast Cancer Treatment Studies (70 papers). Jin Seok Ahn collaborates with scholars based in South Korea, United States and United Kingdom. Jin Seok Ahn's co-authors include Keunchil Park, Myung‐Ju Ahn, Jong‐Mu Sun, Se‐Hoon Lee, Young‐Hyuck Im, Yoon‐La Choi, Yeon Hee Park, Jong‐Mu Sun, Shirish M. Gadgeel and Bogdana Balas and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jin Seok Ahn

429 papers receiving 13.3k citations

Hit Papers

Alectinib versus Crizotin... 2015 2026 2018 2022 2017 2015 2020 2019 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
    2017 1.6k citations Jin Seok Ahn, Dong‐Wan Kim et al. profile →
  2. Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
    2015 430 citations Jin Seok Ahn et al. Journal of Clinical Oncology profile →
  3. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
    2020 414 citations Jin Seok Ahn et al. Annals of Oncology profile →
  4. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
    2019 322 citations Jong‐Mu Sun, Jin Seok Ahn et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jin Seok Ahn 8.6k 7.8k 3.2k 3.0k 1.1k 452 13.5k
Shirish M. Gadgeel 10.1k 1.2× 10.1k 1.3× 4.2k 1.3× 2.7k 0.9× 1.1k 0.9× 411 15.3k
Ji‐Youn Han 9.6k 1.1× 8.2k 1.1× 3.1k 1.0× 2.1k 0.7× 837 0.7× 257 13.1k
Heather A. Wakelee 6.9k 0.8× 7.5k 1.0× 3.9k 1.2× 4.0k 1.3× 1.2k 1.1× 447 13.5k
Julien Mazières 10.7k 1.2× 9.7k 1.2× 5.7k 1.8× 3.0k 1.0× 1.3k 1.2× 441 17.0k
Keyue Ding 8.1k 0.9× 8.4k 1.1× 3.4k 1.1× 2.6k 0.9× 1.0k 0.9× 218 14.5k
Stefan Sleijfer 7.1k 0.8× 4.7k 0.6× 4.2k 1.3× 3.5k 1.2× 1.3k 1.1× 379 13.6k
Hedy L. Kindler 8.4k 1.0× 7.3k 0.9× 3.6k 1.1× 3.1k 1.0× 860 0.8× 400 16.1k
Beow Y. Yeap 7.1k 0.8× 10.3k 1.3× 3.1k 1.0× 2.2k 0.7× 1.1k 1.0× 206 14.4k
Igor Bondarenko 13.3k 1.5× 9.0k 1.2× 3.3k 1.0× 3.6k 1.2× 1.3k 1.1× 317 17.7k
Vivek Subbiah 6.0k 0.7× 4.6k 0.6× 3.7k 1.2× 3.1k 1.0× 1.7k 1.5× 599 12.2k

Countries citing papers authored by Jin Seok Ahn

Since Specialization
Citations

This map shows the geographic impact of Jin Seok Ahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin Seok Ahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin Seok Ahn more than expected).

Fields of papers citing papers by Jin Seok Ahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin Seok Ahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin Seok Ahn. The network helps show where Jin Seok Ahn may publish in the future.

Co-authorship network of co-authors of Jin Seok Ahn

This figure shows the co-authorship network connecting the top 25 collaborators of Jin Seok Ahn. A scholar is included among the top collaborators of Jin Seok Ahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin Seok Ahn. Jin Seok Ahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cho, Eun Yoon, Jeong Eon Lee, Hae Hyun Jung, et al.. (2025). Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype. Cell Reports Medicine. 6(6). 102164–102164. 2 indexed citations
2.
Park, Sehhoon, Jong‐Mu Sun, Se‐Hoon Lee, et al.. (2025). A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer. European Journal of Cancer. 230. 115805–115805. 1 indexed citations
3.
Kang, Danbee, Ho Young Kim, Soo‐Yeon Kim, et al.. (2024). Emulating trial to evaluate the effectiveness of routine supportive care on mortality among cancer patients experiencing distress at the time of diagnosis. Journal of Affective Disorders. 354. 519–525. 1 indexed citations
4.
Lim, Ho Yeong, Jin Seok Ahn, Joon Oh Park, et al.. (2024). Updated safety, efficacy, pharmacokinetics, and biomarkers from the phase 1 study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2642–2642. 2 indexed citations
5.
Park, Yeon Hee, Kyung-Hun Lee, Gun Min Kim, et al.. (2024). Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.. Journal of Clinical Oncology. 42(17_suppl). LBA1002–LBA1002. 1 indexed citations
6.
Park, Sehhoon, Hyun Ae Jung, Jong‐Mu Sun, et al.. (2024). Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM). Journal of Clinical Oncology. 42(23). 2747–2756. 23 indexed citations
7.
Kang, Danbee, Soo-Yeon Kim, Youngha Kim, et al.. (2023). Efficacy of the PRO-CTCAE mobile application for improving patient participation in symptom management during cancer treatment: a randomized controlled trial. Supportive Care in Cancer. 31(6). 321–321. 11 indexed citations
8.
Oh, Jung Min, Joon Jeong, Seok Won Kim, et al.. (2023). Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer. Cancers. 15(19). 4720–4720. 2 indexed citations
9.
Kim, Nalee, Haeyoung Kim, Won Park, et al.. (2023). Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach. Radiation Oncology. 18(1). 3 indexed citations
10.
Lim, Ho Yeong, et al.. (2023). 1035P Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors. Annals of Oncology. 34. S629–S629. 1 indexed citations
11.
Park, Sehhoon, Yu Jung Kim, Young Joo Min, et al.. (2023). Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. Cancer. 130(4). 541–552. 15 indexed citations
12.
Jo, Hyunji, Seri Park, Hye Ryeon Kim, et al.. (2022). Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort. Cancers. 14(19). 4839–4839. 6 indexed citations
13.
Kim, Kyung Hwan, Jinhyun Cho, Bo Mi Ku, et al.. (2019). The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clinical Cancer Research. 25(7). 2144–2154. 132 indexed citations
14.
Park, Sehhoon, Hayoon Lee, Boram Lee, et al.. (2019). DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. Journal of Thoracic Oncology. 14(9). 1640–1650. 58 indexed citations
15.
Lee, Ji Yun, Jong‐Mu Sun, Sung Hee Lim, et al.. (2015). A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. Clinical Cancer Research. 22(9). 2139–2145. 28 indexed citations
16.
17.
Kim, Young-Wook, Jeong‐Hun Ko, Amir Abolhoda, et al.. (2012). The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor. Molecular Cancer Therapeutics. 11(3). 784–791. 144 indexed citations
18.
Park, Sarah, Jeeyun Lee, Young Hyeh Ko, et al.. (2007). The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 110(3). 972–978. 242 indexed citations
19.
Choi, Chul Won, Byung‐Soo Kim, Jae Hong Seo, et al.. (2001). Response to high‐dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. American Journal of Hematology. 66(3). 197–202. 1 indexed citations
20.
Choi, Chul Won, Byung‐Soo Kim, Jae Hong Seo, et al.. (2001). Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. American Journal of Hematology. 66(3). 197–202. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shirish M. Gadgeel Breakdown of academic impact, for papers by Ji‐Youn Han Breakdown of academic impact, for papers by Heather A. Wakelee Breakdown of academic impact, for papers by Julien Mazières Breakdown of academic impact, for papers by Keyue Ding Breakdown of academic impact, for papers by Stefan Sleijfer Breakdown of academic impact, for papers by Hedy L. Kindler Breakdown of academic impact, for papers by Beow Y. Yeap Breakdown of academic impact, for papers by Igor Bondarenko Breakdown of academic impact, for papers by Vivek Subbiah
Rankless by CCL
2026